You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed Acute Promyelocytic Leukemia

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Newly-diagnosed APL (de Novo or Therapy-related), Relapsed APL Trial in Dresden (observational)

Recruiting
  • Newly-diagnosed APL (de Novo or Therapy-related)
  • Relapsed APL
  • observational
  • Dresden, Germany
    Prof. Dr. U. Platzbecker
Aug 10, 2022

The Acute Promyelocytic Leukaemia Asian Consortium Project

Recruiting
  • Acute Promyelocytic Leukemia
    • Hong Kong, Hong Kong
      Department of Medicine, the University of Hong Kong, Queen Mary
    Oct 3, 2022

    APL Trial in Shanghai (Chidamide+venetoclax)

    Active, not recruiting
    • APL
    • Shanghai, Shanghai, China
      Jiong HU
    May 30, 2023

    Acute Promyelocytic Leukemia, Induction Therapy, Oral Trial in Beijing (Etoposide, Daunorubicin)

    Recruiting
    • Acute Promyelocytic Leukemia
    • +2 more
    • Beijing, Beijing, China
      Peking University Institute of Hematology
    Apr 26, 2023

    AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed

    Recruiting
    • AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
    • MRD-triggered arm
    • Prophylactic Arm
    • Heidelberg, BW, Germany
      University Hospital Heidelberg Med5
    Jan 4, 2021

    Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

    Recruiting
    • Acute Myeloid Leukemia Refractory
    • Acute Myeloid Leukemia, in Relapse
    • anti Tim-3/CD123 CAR-T cell therapy
    • Xuzhou, Jiangsu, China
      Kailin Xu
    Nov 4, 2023

    Relapsed Adult ALL, Relapsed Adult AML Trial in Changchun (Plerixafor)

    Active, not recruiting
    • Relapsed Adult ALL
    • Relapsed Adult AML
    • Changchun, Jilin, China
      First Hospital of Jilin University
    Nov 19, 2023

    Acute Promyelocytic Leukemia Trial in United States (SY-2101, Arsenic Trioxide)

    Recruiting
    • Acute Promyelocytic Leukemia
    • Birmingham, Alabama
    • +4 more
    Jul 12, 2022

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • Acute Lymphoblastic Leukemia With Failed Remission
    • São Paulo, SP, Brazil
      Instituto do Cancer do Estado de Sao Paulo
    Sep 12, 2023

    Acute Myeloid Leukemia Trial in Beijing (Ven+CAG)

    Recruiting
    • Acute Myeloid Leukemia
    • Beijing, Beijing, China
      Peking University People's Hospital
    Jun 23, 2023

    Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

    Recruiting
    • Acute Myeloid Leukemia
    • +3 more
    • CD123 targeted CAR-NK cells
    • Taiyuan, Shanxi, China
      Shanxi Bethune Hospital
    Aug 28, 2023

    AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

    Not yet recruiting
    • AML
    • +11 more
    • (no location specified)
    Aug 14, 2023

    Promyelocytic Leukemia Trial in Monterrey (Arsenic trioxide, all-trans retinoic acid)

    Recruiting
    • Promyelocytic Leukemia
    • Arsenic trioxide
    • all-trans retinoic acid
    • Monterrey, Nuevo Leon, Mexico
      Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitari
    Aug 9, 2022

    B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

    Not yet recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • HY004
    • +2 more
    • (no location specified)
    Aug 18, 2023

    Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)

    Recruiting
    • Relapsed/Refractory Acute Myeloid Leukemia
    • B7-H3 target, CAR gene modified gdT cell injection
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital， Zhejiang University School of Med
    Feb 15, 2023

    B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • QH103 Cell Injection
    • +2 more
    • Hefei, Anhui, China
      Anhui Provincial Hospital
    Sep 21, 2023

    Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

    Not yet recruiting
    • Acute Myeloid Leukemia, in Relapse
    • Acute Myeloid Leukemia Refractory
    • (no location specified)
    Nov 9, 2023

    Relapsed or Refractory Acute Myeloid Leukemia Trial in Taiyuan (Selinexor, Homoharringtonine, Daunorubicin)

    Recruiting
    • Relapsed or Refractory Acute Myeloid Leukemia
    • Taiyuan, Shanxi, China
      Tao Wang
    Feb 9, 2023

    B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

    Not yet recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • (no location specified)
    Oct 10, 2023

    T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

    Not yet recruiting
    • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    • CD7-CART01
    • (no location specified)
    Sep 26, 2023

    Relapsed/Refractory Acute Myeloid Leukemia Trial in Hefei (gdT cell injection targeting B7-H3 chimeric antigen receptor)

    Recruiting
    • Relapsed/Refractory Acute Myeloid Leukemia
    • gdT cell injection targeting B7-H3 chimeric antigen receptor
    • Hefei, Anhui, China
      PersonGen Anke Cellular Therapeutice Co., Ltd.
    Jan 31, 2023

    Relapsed/Refractory Acute Myeloid Leukemia Trial in Beijing

    Recruiting
    • Relapsed/Refractory Acute Myeloid Leukemia
    • Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
    • Best-Available Therapy(BAT) Regimen
    • Beijing, Beijing, China
      Chinese PLA General Hospital
    Oct 10, 2023

    Acute Myeloid Leukemia (Relapsed/Refractory) Trial in Suzhou (Selinexor, Chidamide)

    Recruiting
    • Acute Myeloid Leukemia (Relapsed/Refractory)
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jul 16, 2023

    Relapsed/Refractory AML Trial in Suzhou (Selinexor, Homoharringtonine, Cytarabine)

    Not yet recruiting
    • Relapsed/Refractory AML
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Mar 28, 2023

    PET-CT Imaging in Relapsed/Refractory Acute Leukemias

    Not yet recruiting
    • B Cell
    • +2 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Aug 4, 2023